77
Participants
Start Date
March 31, 2007
Primary Completion Date
September 30, 2008
Study Completion Date
December 31, 2008
orally disintegrating selegiline (Zelapar)
1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
Parkinson's Disease and Movement Disorder Center of Boca Raton, Boca Raton
University of South Florida, Tampa
University of Toledo, Toledo
Henry Ford Health Center - Franklin Pointe, Southfield
Methodist Plaza Speciality Clinic, Des Moines
Struthers Parkinson's Center, Golden Valley
University of Kansas Medical Center, Kansas City
Ochsner Clinic Foundation, New Orleans
Neurology Specialists Dallas, Dallas
ETMC Neurological Institute, Tyler
University of Southern California, Los Angeles
Coastal Neurological Medical Group, Inc, La Jolla
University of California - Irvine, Irvine
The Parkinson's Institute, Sunnyvale
Beth Israel Deaconess Medical Center, Boston
Harvard Vanguard Medical Associates, Boston
NeuroHealth Parkinson Disease and Movement Disorder Center, Warwick
Bausch Health Americas, Inc.
INDUSTRY
Parkinson's Disease and Movement Disorder Center of Boca Raton
OTHER